Axonics Modulation Technologies (AXNX – Research Report) received a Hold rating and price target from Wolfe Research analyst Michael Polark yesterday. The company’s shares closed yesterday at $69.36.

Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.01 per share a year ...

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report), with a price target of $71.00. The company’s ...

Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.08 per share a year ...

Medtronic said it will seek to overturn the verdict, and will continue its separate cases against Axonics at the ITC and in Delaware federal court. (Getty Images/Zolnierek) A federal jury in ...

IRVINE, Calif. (AP) — IRVINE, Calif. (AP) — Axonics Modulation Technologies Inc. (AXNX) on Thursday reported a third-quarter loss of $21,000, after reporting a profit in the same period a year earlier ...

The legal spat dates back to late 2019, when Medtronic first filed suit against Axonics, claiming that certain aspects of the company’s sacral neuromodulation implants infringe on seven patents ...